alogliptin and Coronary-Stenosis

alogliptin has been researched along with Coronary-Stenosis* in 1 studies

Other Studies

1 other study(ies) available for alogliptin and Coronary-Stenosis

ArticleYear
Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study.
    Journal of cardiology, 2017, Volume: 69, Issue:3

    Patients with type 2 diabetes are at high risk for developing coronary artery disease (CAD). Noninvasive anatomic assessment by coronary computed tomography angiography (CCTA) is being increasingly used for detecting or excluding CAD. Recently, fractional flow reserve (FFR) using routinely acquired CCTA datasets (FFR. This study will be a prospective, non-randomized, multicenter trial performed in Japan. Patients with type 2 diabetes who have intermediate coronary artery stenosis (diameter stenosis <70%) as evaluated by CCTA will be treated with 25mg/day of alogliptin. After 48 weeks' treatment, CCTA will be repeated. The primary endpoint will be changes in FFR. This study will be the first multicenter trial to evaluate the effects of alogliptin on coronary atherosclerosis using the newly developed FFR

    Topics: Aged; Carotid Intima-Media Thickness; Computed Tomography Angiography; Coronary Angiography; Coronary Stenosis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Fractional Flow Reserve, Myocardial; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Piperidines; Plaque, Atherosclerotic; Prospective Studies; Uracil

2017